

CITATION REPORT

List of articles citing

Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy

DOI: 10.1159/000020248

European Urology, 2000, 38, 30-4.

Source: <https://exaly.com/paper-pdf/31114144/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. <i>BJU International</i> , 2000 , 86, 469-73	5.6	31
50	Sildenafil citrate: a therapeutic update. <i>Clinical Therapeutics</i> , 2001 , 23, 2-23	3.5	65
49	Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. <i>Current Opinion in Urology</i> , 2001 , 11, 625-30	2.8	2
48	Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents. <i>BJU International</i> , 2001 , 88, 596-601	5.6	1
47	What's new in urology. <i>Journal of the American College of Surgeons</i> , 2001 , 193, 179-201	4.4	1
46	Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. <i>International Journal of Impotence Research</i> , 2002 , 14, 50-3	2.3	51
45	Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in patients with erectile dysfunction. <i>International Journal of Impotence Research</i> , 2002 , 14, 38-43	2.3	19
44	Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. <i>International Journal of Impotence Research</i> , 2002 , 14, 38-43	2.3	34
43	Combination therapy for erectile dysfunction: where we are and what's in the future. <i>Current Urology Reports</i> , 2002 , 3, 467-70	2.9	11
42	Pharmacological management of erectile dysfunction. <i>BJU International</i> , 2003 , 91, 446-54	5.6	74
41	Hypogonadism and erectile dysfunction: the role for testosterone therapy. <i>International Journal of Impotence Research</i> , 2003 , 15 Suppl 4, S9-13	2.3	42
40	Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. <i>Endocrine Practice</i> , 2003 , 9, 52-63	3.2	10
39	Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. <i>Journal of Sexual Medicine</i> , 2004 , 1, 292-300	1.1	95
38	Future options for combination therapy in the management of erectile dysfunction in older men. <i>Drugs and Aging</i> , 2004 , 21, 555-64	4.7	26
37	Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy. <i>EAU Update Series</i> , 2004 , 2, 75-83		11
36	Use of intraurethral alprostadil in patients not responding to sildenafil citrate. <i>Urology</i> , 2004 , 63, 951-4	1.6	26
35	Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. <i>BJU International</i> , 2005 , 95, 843-6	5.6	46

34	Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy. 2005 , 253-277		1
33	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , 2005 , 65, 1621-50	12.1	133
32	Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. <i>Drugs and Aging</i> , 2006 , 23, 101-17	4.7	37
31	Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance?. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006 , 3, 342-349		5
30	Management of sildenafil treatment failures. <i>Current Opinion in Urology</i> , 2006 , 16, 449-59	2.8	33
29	Treating erectile dysfunction when PDE5 inhibitors fail. <i>BMJ, The</i> , 2006 , 332, 589-92	5.9	82
28	Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1214-30	2.9	17
27	Intraurethral alprostadil for erectile dysfunction: a review of the literature. <i>Drugs</i> , 2012 , 72, 2243-54	12.1	38
26	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 130-71	1.1	117
25	[Drugs for sexual medicine]. <i>Progres En Urologie</i> , 2013 , 23, 1299-311	0.9	1
24	Alprostadil for the treatment of impotence. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 421-8	4	38
23	The role of intraurethral alprostadil as a first-choice erectile dysfunction treatment option in special populations: a proposed treatment algorithm. <i>Clinical Practice (London, England)</i> , 2014 , 11, 17-26 ³		2
22	Nonresponse to PDE5 inhibitors in erectile dysfunction. Part 2. <i>Human Andrology</i> , 2014 , 4, 45-53	1	
21	Current Diagnosis and Management of Erectile Dysfunction. <i>Current Sexual Health Reports</i> , 2014 , 6, 164-176		41
20	Intraurethral alprostadil in the management of erectile dysfunction: a reappraisal of the clinical evidence. <i>Clinical Practice (London, England)</i> , 2014 , 11, 3-15	3	1
19	Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). <i>Journal of Sexual Medicine</i> , 2016 , 13, 465-88	1.1	110
18	Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. <i>Drugs and Aging</i> , 2018 , 35, 175-187	4.7	12
17	Les traitements oraux de la dysfonction érectile aujourd'hui, pour quel patient?. <i>Sexologies</i> , 2018 , 27, 37-46	0.5	0

16	Additional non-invasive options can be considered for erectile dysfunction when phosphodiesterase type 5 inhibitors fail. <i>Drugs and Therapy Perspectives</i> , 2018 , 34, 567-571	1.5	
15	Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. <i>International Journal of Impotence Research</i> , 2018 , 30, 203-208	2.3	16
14	The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
13	Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. <i>International Journal of Impotence Research</i> , 2021 ,	2.3	2
12	Evaluation and Management of Erectile Dysfunction. 2012 , 721-748.e7		6
11	Sexual Aspects of Prostate Cancer Treatment. 2003 , 471-480		
10	Sexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 Inhibitors. 2005 , 409-421		
9	Erectile Dysfunction. 2005 , 193-223		
8	Urologic/Clinical Treatment of Erectile Dysfunction. 2016 , 53-63		
7	Acute Toxicities of Therapy: Urologic Complications. 2006 , 1435-1442		
6	Topical and Intra-Urethral Therapy. 2006 , 303-321		
5	Sexual dysfunction after radical prostatectomy. <i>Reviews in Urology</i> , 2005 , 7 Suppl 2, S3-S10	1	9
4	Oral and non-oral combination therapy for erectile dysfunction. <i>Reviews in Urology</i> , 2007 , 9, 99-105	1	7
3	Progress and prospect of stem cell therapy for diabetic erectile dysfunction.. <i>World Journal of Diabetes</i> , 2021 , 12, 2000-2010	4.7	0
2	Comprehensive Perspectives for Erectile Dysfunction Pharmacotherapy: from Mechanism to Application. <i>Current Medicinal Chemistry</i> , 2022 , 29,	4.3	0
1	The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors.		2